← Files Rhizome AIARCHIVED FILE
.codex-plugin/plugin.json
5.59 KB · Nov 21, 2026 · 06:10 UTC
{
"author": {
"name": "Rhizome AI"
},
"description": "Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases.\n\nOur customers are leveraging it to:\n\n- Build regulatory strategies\n- Understand clinical expectations\n- Keep an eye on competitive intel\n- Write and review HA-facing documents\n\nOur datasets cover:\n\n- FDA: drug, biologic and device approvals (Drugs@FDA, Purple Book, Orange Book, 510(k)/De Novo, PMA), DailyMed labels, guidance (including product-specific guidance), advisory committees, CRLs, warning and untitled letters, 483s and inspections, recalls, orphan designations, clinical trials, the CFR and the Federal Register\n- EMA and EU: EPARs, guidelines, committee documents, orphan and PIP decisions, CTIS and EU CTR trials, EudraLex, MDCG guidance, EUDAMED devices and certificates\n- UK MHRA, Health Canada, Swissmedic, TGA (Australia) and BfArM/PEI (Germany): approvals and assessment reports, guidance, regulations and clinical trials\n- International standards: ICH, IMDRF, PIC/S, ISO and GHWP\n- US market access: CMS coverage decisions, HCPCS codes and Part B drug pricing\n- Competitive context: SEC filings, patents and PTAB decisions, PubMed, and RAPS/DIA regulatory news\n\nEnterprise accounts can also search 50+ more databases, all translated to English:\n\n- Japan PMDA: review reports, guidance, the Japanese Pharmacopoeia, and jRCT/UMIN clinical trials\n- China NMPA/CDE: product reviews, CDE acceptances, guidance, regulations, announcements and consultations, clinical trials (including ChiCTR), and human genetic resources rules\n- South Korea MFDS: review reports, drug, biologic and device regulations, guidance, notifications and clinical trials\n- Brazil ANVISA: guidance, legislation, clinical research guidance and CONEP resolutions\n- Taiwan TFDA/CDE: guidance, announcements, drug safety communications, regulatory notices and drug/device laws\n- More jurisdictions: Argentina ANMAT, India CDSCO, South Africa SAHPRA, Saudi SFDA, T\u00fcrkiye T\u0130TCK, Israel MoH and UAE EDE\n- FDA adverse events: FAERS (drugs) and MAUDE (devices)\n- Health Canada: clinical study reports through PRCI\n\nSupport: support@rhizomeai.com",
"interface": {
"capabilities": [],
"category": "Healthcare",
"defaultPrompt": [
"what do I need to do for an oncology IND for the FDA?",
"what clinical trial sample sizes are typical for autoimmune rare disease therapies?",
"what are ideal predicates for full-body ultrasound scan that detects body comp and tries to find cancer?"
],
"developerName": "Rhizome AI",
"displayName": "Rhizome AI",
"longDescription": "Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases.\n\nOur customers are leveraging it to:\n\n- Build regulatory strategies\n- Understand clinical expectations\n- Keep an eye on competitive intel\n- Write and review HA-facing documents\n\nOur datasets cover:\n\n- FDA: drug, biologic and device approvals (Drugs@FDA, Purple Book, Orange Book, 510(k)/De Novo, PMA), DailyMed labels, guidance (including product-specific guidance), advisory committees, CRLs, warning and untitled letters, 483s and inspections, recalls, orphan designations, clinical trials, the CFR and the Federal Register\n- EMA and EU: EPARs, guidelines, committee documents, orphan and PIP decisions, CTIS and EU CTR trials, EudraLex, MDCG guidance, EUDAMED devices and certificates\n- UK MHRA, Health Canada, Swissmedic, TGA (Australia) and BfArM/PEI (Germany): approvals and assessment reports, guidance, regulations and clinical trials\n- International standards: ICH, IMDRF, PIC/S, ISO and GHWP\n- US market access: CMS coverage decisions, HCPCS codes and Part B drug pricing\n- Competitive context: SEC filings, patents and PTAB decisions, PubMed, and RAPS/DIA regulatory news\n\nEnterprise accounts can also search 50+ more databases, all translated to English:\n\n- Japan PMDA: review reports, guidance, the Japanese Pharmacopoeia, and jRCT/UMIN clinical trials\n- China NMPA/CDE: product reviews, CDE acceptances, guidance, regulations, announcements and consultations, clinical trials (including ChiCTR), and human genetic resources rules\n- South Korea MFDS: review reports, drug, biologic and device regulations, guidance, notifications and clinical trials\n- Brazil ANVISA: guidance, legislation, clinical research guidance and CONEP resolutions\n- Taiwan TFDA/CDE: guidance, announcements, drug safety communications, regulatory notices and drug/device laws\n- More jurisdictions: Argentina ANMAT, India CDSCO, South Africa SAHPRA, Saudi SFDA, T\u00fcrkiye T\u0130TCK, Israel MoH and UAE EDE\n- FDA adverse events: FAERS (drugs) and MAUDE (devices)\n- Health Canada: clinical study reports through PRCI\n\nSupport: support@rhizomeai.com",
"privacyPolicyURL": "https://rhizomeai.com/privacypolicy",
"shortDescription": "Cited FDA & EMA Answers",
"supportURL": "https://rhizomeai.com",
"termsOfServiceURL": "https://rhizomeai.com/termsofservice",
"websiteURL": "https://rhizomeai.com",
"logo": "./assets/logo.png",
"logoDark": "./assets/logo-dark.png",
"composerIcon": "./assets/icon.png",
"composerIconDark": "./assets/icon-dark.png"
},
"name": "app-6a63bad25528819187bf1eeabd8a9af3",
"version": "3.2.0",
"mcpServers": "./.mcp.json",
"extensions": {
"com.openai": {
"publication": {
"release_notes": "Listing update: new subtitle and description. No tool or server changes."
}
}
},
"apps": "./.app.json"
}
SHA-256: 338c63598b9bbe1be1d715765136f14d2e98ff532f8353fbd7c7286cab32e9f8